Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

Abstract: In one preferred embodiment, a set of air interface protocols (AIPs) provides a method for secure wireless-to-IP communication between conveyance-mounted security sensors and one or more remote data consolidation centers employing a global ad-hoc network topology, comprising one or more on-conveyance sensing devices; one or more on-conveyance wireless communications devices; one or more wireless-to-IP bridging devices; one or more internet-addressable remote data centers; wherein the remote data center contains computer instructions for: commanding secure AIP-compliant operations; and maintaining a data base of security sensor-related events interfacing to an encryption key management facility.